摘要
目的探讨调脂联合抗栓治疗冠心病的临床效果。方法将60例冠心病患者随机分为观察组和对照组,每组30例。对照组采用常规抗栓治疗(阿司匹林+氯吡格雷),观察组在对照组治疗基础上采用他汀类降脂。比较2组的临床疗效、血脂水平、炎性因子水平及心血管不良事件发生情况。结果观察组总有效率显著高于对照组(90.0%比76.7%,P<0.05),而心血管不良事件发生率显著低于对照组(3.3%比13.3%,P<0.05);2组治疗后血脂与炎性因子水平较治疗前均显著降低(P<0.05),观察组治疗后血脂水平与炎性因子水平较对照组降低更为显著(P<0.05)。结论调脂联合抗栓治疗冠心病能够降低炎性因子对心肌的损害,延缓动脉粥样硬化的进程,改善患者的预后。
Objective To investigate the clinical effect of lipid-lowering therapy combined with antithrombotic treatment on coronary heart disease. Methods Sixty patients with coronary heart disease were randomly divided into two groups, with 30 patients in each group. The control group was given conventional antithrombotic treatment （aspirin plus clopidogrel）. The observation group was given statins based on antithrombotic treatment. Clinical efficacy, blood lipid, inflammatory cytokines and cardiovascular adverse events were compared between the two groups. Results Compared with control group, lipid-lowering therapy increased the total effective rate（90.0% vs 76.7%,P〈0.05）,and decreased the incidence of cardiovascular adverse events（3.3% vs 13.3%,P〈0.05）. After treatment, levels of blood lipid and inflammatory cytokines significantly decreased in both group （P〈0.05）, and the decrease in observation group was more obvious than that in control group （P〈0.05）. Conclusion Lipid-lowering therapy combined with antithrombotic treatment can reduce inflammatory cytokine-induced myocardial damage, delay the progress of atherosclerosis and improve the prognosis in patients with coronary heart disease.
出处
《实用临床医学（江西）》
CAS
2014年第6期3-5,共3页
Practical Clinical Medicine
关键词
抗栓治疗
调脂
阿托伐他汀
冠心病
血脂
炎性因子
antithrombotic treatment
lipid-lowering therapy
atorvastatin
coronary heart disease
blood lipid
inflammatory cytokines
